Safety Holds for Two CD19 CAR-T Programs

Novartis (NVS) suspended patient screening, randomization, and dosing in eight autoimmune and neurological clinical trials on August 24, 2026, following three cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS) and subsequent deaths after rap-cel administration. Rap-cel, also known as rapcabtagene autoleucel (non-proprietary name), is an autologous CAR-T therapy that targets CD19-positive B cells using patient-derived T cells. It was under development for lupus, lupus nephritis, myasthenia gravis, multiple sclerosis, and other conditions, including a Phase 2 trial. The oncology Phase 1/2 program remains unaffected, with the focus now on determining whether toxicity is linked to patient disease status, prior treatments, or patterns of immune cell expansion.

BMS Voluntarily Halts All zola-cel Programs

Bristol Myers Squibb (BMY) voluntarily paused zola-cel enrollment after detecting transient and reversible inflammatory events during safety monitoring. Zola-cel, also known as zolacabtagene autoleucel (non-proprietary name), BMS-986353, or CC-97540, is an autologous CAR-T targeting CD19 and manufactured using the rapid NEX-T process. One case of IEC-HS had already been reported in the Phase 1 systemic lupus erythematosus trial, and the program was expanding into Phase 2 autoimmune cytopenia and comparative systemic sclerosis trials. This review will impact platform-wide dosing, pre-treatment, and monitoring standards.

Risk Tolerance Lower in Autoimmune Market Than Efficacy

Unlike oncology, autoimmune diseases have approved therapies such as belimumab (Benlysta), anifrolumab (Saphnelo), and voclosporin (Lupkynis), which limit regulatory and physician tolerance for life-threatening toxicity. The systemic lupus erythematosus treatment market was estimated at approximately USD 2.4 billion in 2024, and CAR-T had strong commercial appeal due to the potential to replace repeated dosing with a one-time treatment. However, rapid manufacturing may be linked to strong in vivo expansion, increasing the need for inpatient care, intensive monitoring, and toxicity management, which could weaken the economic viability of one-time treatments.

Competitive Landscape and Regulatory Path Reassessment

Cabaletta Bio (CABA)'s CD19 CAR-T rese-cel is in registration trials for myositis and Phase 1/2 trials for lupus, systemic sclerosis, and myasthenia gravis. Kyverna Therapeutics (KYTX)'s miv-cel has entered Phase 3 for myasthenia gravis. Neither rap-cel nor zola-cel has received FDA, EMA, or PMDA approval, nor have they undergone AdComm voting. The current actions are company-led temporary halts and are in the regulatory discussion phase. How Novartis and BMS set conditions for resuming trials after toxicity review will serve as a sector benchmark for the clinical design, patient selection, and regulatory requirements for later-stage CD19 CAR-T programs.